For MA payers and care management leaders, this is not a distant concern. It is a compounding financial and clinical problem that touches every corner of plan performance, from risk adjustment revenue to total cost of care.
This guide breaks down why the dementia detection gap persists in Medicare Advantage and what a modern early screening strategy looks like in practice. Whether you oversee population health, clinical operations, or quality performance, you will find a structured path forward.
Key Takeaways: Closing the Dementia Detection Gap in Medicare Advantage
- An estimated 61% of dementia cases among Medicare beneficiaries remain undiagnosed, driving hidden costs across care settings.
- CMS-HCC V28 now classifies dementia into three severity tiers, making documentation specificity essential for accurate risk adjustment.
- Undetected cognitive impairment inflates emergency utilization, hospitalizations, and total cost of care for MA plans.
- Neurotrack gives MA plans population-level cognitive visibility through clinically validated digital screening embedded in existing workflows.
- Pairing early cognitive screening with structured coding and care pathways creates measurable improvements in plan performance and member outcomes.
Why Does Dementia Go Undetected in Medicare Advantage Populations?
The gap between actual dementia prevalence and documented diagnoses is one of the largest unmanaged cost drivers in Medicare Advantage. According to the Alzheimer's Association (2025), 61% of dementia cases go undiagnosed.
Among MA members, this underdetection creates a dual financial problem. Plans absorb the elevated costs of a high-acuity population while forgoing the risk adjustment revenue that accurate documentation would capture.
Several systemic barriers drive this gap. Primary care physicians face significant time constraints during Annual Wellness Visits. Traditional paper-based screening tools lack the sensitivity to detect cognitive change at the mild cognitive impairment (MCI) stage. And more than half of physicians report patient stigma as a deterrent to initiating cognitive conversations.
Without a reliable, scalable approach to routine cognitive baseline assessment, plans remain blind to a condition that directly affects utilization patterns, comorbidity management, and quality scores.
What Is the Financial Impact of Undiagnosed Dementia on MA Plans?
Undiagnosed dementia does not simply represent a missed diagnosis. It represents a cascade of avoidable costs that compound across every care setting. Average annual Medicare spending per member with dementia exceeds $22,500, roughly three times higher than spending for members without a dementia diagnosis.
For MA plans operating under capitated or risk-bearing arrangements, the financial exposure works in two directions. Undetected cognitive impairment drives preventable emergency department visits, unplanned hospitalizations, and accelerated decline in co-occurring chronic conditions like diabetes and heart failure.
Because these conditions never appear in the medical record, plans simultaneously miss the risk adjustment revenue that accurate documentation would produce. The result is excess cost paired with structural underpayment.
Dementia-related healthcare costs in the United States exceeded $360 billion in 2024, according to the Alzheimer's Association. For plans managing large Medicare populations, even small improvements in detection rates translate into significant financial and clinical returns.
How Does CMS-HCC V28 Change Dementia Coding and Documentation?
Payment year 2026 marks the first year that risk scores are calculated entirely under the CMS-HCC V28 model, with no residual V24 blending. For dementia specifically, V28 introduces a three-tier severity classification that fundamentally changes how plans approach coding and documentation.
Under V28, dementia maps to three Hierarchical Condition Categories: HCC 125 (severe), HCC 126 (moderate), and HCC 127 (mild or unspecified). All three tiers carry a community non-dual aged RAF coefficient of 0.341. The critical change is that behavioral disturbance documentation now determines tier placement, making clinical specificity essential.
V28 also reduced the total number of ICD-10-CM codes mapping to payment HCCs from roughly 9,800 to 7,770. This means every legitimately documented chronic condition carries relatively more weight. Missed annual recapture of a dementia diagnosis has a larger proportional impact on a member's RAF score than it did under V24.
For health plan coding teams, the practical implication is clear: suspecting logic built for V24 must be retired entirely. Prospective workflows need to surface conditions that are payable under V28, clinically probable for the member, and due for annual recapture.
What Documentation Standards Support Compliant Dementia Coding?
A diagnosis code is only as defensible as the clinical note behind it. The widely accepted standard for risk-adjusted documentation is MEAT: Monitor, Evaluate, Assess/Address, and Treat. Each chronic condition, including dementia, must be supported by at least one of these elements during a qualifying face-to-face encounter.
For dementia specifically, documentation must go beyond a problem-list entry. The provider needs to record the dementia severity level, the presence or absence of behavioral disturbance, and any underlying etiology.
Causal language linking dementia to conditions like Parkinson's disease or cerebrovascular disease is necessary for combination codes. Coders cannot infer these relationships without explicit provider documentation.
RADV audits have moved from occasional to universal. CMS now plans to audit every eligible Medicare Advantage contract annually, with extrapolated recoveries in play. A compliant documentation strategy starts at the point of care, not in retrospective chart review.
Why Does Early Cognitive Screening Matter for Risk Adjustment Accuracy?
Risk adjustment accuracy depends on documented diagnoses that reflect actual clinical reality. When cognitive impairment goes unscreened and unrecorded, the resulting RAF score underrepresents the true complexity of your member population. This underpayment starves care management programs of the funding they need to manage high-acuity members effectively.
Early screening addresses this gap at the source. By identifying cognitive impairment at the MCI stage, plans gain lead time to document accurately, initiate care pathways, and capture appropriate risk adjustment revenue.
Neurotrack enables this approach with digital cognitive assessments that detect impairment earlier and more accurately than traditional paper-based tools. The platform produces structured, EHR-ready documentation aligned with CMS and V28 requirements.
A 2025 Health Affairs study found that when CMS reintroduced dementia to the risk adjustment model, incident dementia diagnosis rates in MA increased by 11.5% relative to traditional Medicare. This increase was concentrated among beneficiaries who were Hispanic or Black, ages 85 and older, or dually eligible for Medicaid.
Financial incentives to detect dementia work. But they only produce results when plans have the screening infrastructure to act on them.
How Can MA Plans Build an Effective Dementia Screening Workflow?
An effective screening strategy does not require a separate clinical encounter or additional specialist referrals. The most scalable approach embeds cognitive screening into existing primary care touchpoints, starting with the Medicare Annual Wellness Visit.
The first step is selecting a screening tool sensitive enough to detect impairment at the MCI stage. Traditional tools like the Mini-Cog, MMSE, and MoCA were designed to identify moderate-to-severe cognitive deficits. They frequently miss early-stage impairment, which is exactly the population where intervention has the greatest impact on outcomes and costs.
Digital cognitive screening tools address this limitation. They standardize administration, eliminate inter-rater variability, and integrate directly into EHR workflows. Neurotrack's cognitive care enablement platform delivers assessments that members can complete in clinic or at home, with automatically scored results flowing into the provider's medical record.
The second step is connecting screening results to a structured clinical pathway. Detection alone does not close the gap. Providers need diagnostic clarity and care planning support to move from a screening result to a documented diagnosis to an actionable care plan. This is where the combination of assessment technology and clinical decision support creates measurable value for plans.
What Role Does Provider Buy-In Play in Closing the Detection Gap?
Even the most accurate screening tool produces limited results if providers are not confident using it or acting on its findings. Clinician hesitancy around cognitive impairment is well documented. Many primary care physicians report feeling uncertain about initiating cognitive conversations, interpreting screening results, or navigating the diagnostic pathway after a positive screen.
Addressing this requires more than a training session. Providers need workflow-embedded tools that reduce the clinical burden of screening while increasing their confidence in the results. When a digital screener can be self-administered by the patient, completed in three minutes, and automatically scored with objective results, the provider's role shifts from test administrator to clinical decision-maker.
Pilot programs have shown that provider adoption increases significantly when screening tools fit into existing visit workflows without adding time. At Desert Oasis Healthcare, implementing Neurotrack's digital assessments led to a 35% net increase in new dementia diagnoses, demonstrating that the right tools drive both provider confidence and clinical outcomes.
How Does the GUIDE Model Affect Dementia Care Strategy for MA Plans?
In 2024, CMS launched the GUIDE Model (Guiding an Improved Dementia Experience), an eight-year demonstration program running through 2032. GUIDE provides structured care coordination, caregiver support, and respite care coverage for community-dwelling beneficiaries with a dementia diagnosis.
For MA plan leaders, GUIDE signals a broader CMS commitment to treating dementia as a managed condition rather than an inevitable decline. The model creates financial incentives for plans to invest in detection infrastructure, care navigation, and caregiver education.
Plans that already have robust screening and documentation workflows will be better positioned to participate in GUIDE-adjacent programs and meet evolving CMS expectations.
The practical takeaway: early detection is the prerequisite for nearly every downstream benefit GUIDE offers. Without a documented diagnosis, members cannot access care coordination, respite coverage, or structured support services.
What Metrics Should MA Plans Track to Measure Detection Gap Progress?
Closing the dementia detection gap is not a one-time initiative. It requires ongoing measurement against specific performance indicators that connect screening activity to financial and clinical outcomes.
Start with screening penetration rate: what percentage of eligible members aged 65 and older received a cognitive assessment in the measurement period? The University of Michigan National Poll on Healthy Aging (2023) found that 80% of adults aged 65 to 80 did not receive a cognitive test in the prior year.
Your plan's screening rate benchmarked against this figure reveals the size of your detection opportunity and provides a baseline for measuring progress.
Next, track the ratio of documented cognitive impairment diagnoses to expected prevalence. If epidemiological data suggests 10% to 12% of your 65-plus population should have a documented diagnosis and your claims data shows 4%, that is a quantifiable detection gap.
Monitor new dementia diagnosis rates, annual recapture rates for existing diagnoses, and the specificity of coded severity levels under V28.
Finally, connect screening metrics to downstream cost and utilization data. Plans implementing routine cognitive screening should expect to see reductions in preventable ER visits, unplanned hospitalizations, and total cost of care for identified members over 12 to 24 months.
How Can Plans Address Health Equity in Dementia Detection?
The dementia detection gap does not affect all populations equally. Black and Hispanic Medicare beneficiaries, dual-eligible members, and those living in rural areas are significantly more likely to have undiagnosed dementia.
The 2025 Health Affairs study confirmed that when financial incentives for detection were introduced, the largest gains in diagnosis rates occurred among these historically underserved populations.
For MA plans committed to equitable care, this disparity represents both a clinical imperative and a strategic opportunity. Closing the detection gap in underserved populations improves Star Ratings quality measures, aligns with CMS equity priorities, and captures risk adjustment revenue that currently goes undocumented.
Effective equity-focused screening strategies use tools designed to minimize cultural and educational bias. Neurotrack's assessments use culturally agnostic symbols and numbers rather than language-dependent tasks, making them accessible across diverse patient populations. Offering remote, patient-led screening options also reduces access barriers for members in rural or transportation-limited settings.
What Does a Comprehensive Dementia Detection Action Plan Look Like?
Building a sustainable detection program requires coordination across clinical operations, coding, quality, and care management. Here is a structured approach MA plan leaders can follow.
Step 1: Assess Your Current Detection Gap
Pull claims and encounter data to compare your documented dementia prevalence against national benchmarks. Identify which provider groups, regions, or member segments have the widest gaps between expected and documented prevalence.
Step 2: Deploy Scalable Screening Infrastructure
Implement digital cognitive screening tools that integrate into existing AWV and primary care workflows. Prioritize tools that produce objective, automatically scored results and generate structured documentation ready for EHR integration.
The Neurotrack platform supports this approach with assessments that fit into existing visit flows without adding provider burden, producing V28-compliant documentation.
Step 3: Align Coding and Documentation Workflows
Retrain coding teams on V28 dementia HCC tiers and MEAT documentation requirements. Build prospective coding workflows that surface suspected cognitive impairment conditions before or during provider encounters, rather than relying on retrospective chart review.
Step 4: Connect Detection to Care Pathways
Screening without follow-through creates no value. Establish clear clinical pathways that connect a positive screening result to diagnostic evaluation, a documented diagnosis, and a patient-specific care plan. Include caregiver education and community resource connections as standard elements of the pathway.
Step 5: Monitor, Measure, and Iterate
Track the metrics outlined above on a quarterly basis. Review screening penetration, new diagnosis rates, recapture rates, and downstream utilization trends. Use this data to identify provider groups that need additional support and member segments where targeted outreach could improve detection.
In Conclusion: How to Close the Dementia Detection Gap in Your MA Plan
The dementia detection gap in Medicare Advantage is not a problem of awareness. Plan leaders, clinicians, and CMS all recognize that millions of members are living with undiagnosed cognitive impairment.
The challenge is operational: building the screening infrastructure, documentation workflows, and clinical pathways that turn recognition into documented diagnoses and actionable care plans.
The convergence of V28's full implementation, universal RADV audits, and CMS programs like GUIDE means the cost of inaction is increasing. Plans that invest in early, routine cognitive screening positioned at the point of care will capture accurate risk adjustment revenue, reduce avoidable utilization, and improve outcomes for their most vulnerable members.
Neurotrack gives Medicare Advantage plans the cognitive care tools to detect impairment earlier, document accurately, and build structured care pathways that produce measurable results. The detection gap is closable. The tools and the evidence both point in the same direction: screen earlier, document precisely, and act decisively.
FAQs About Dementia Detection in Medicare Advantage
What percentage of dementia cases go undiagnosed in Medicare populations?
According to the Alzheimer's Association (2025), approximately 61% of dementia cases among Medicare beneficiaries go undiagnosed. This means the majority of members with cognitive impairment never receive a documented diagnosis, which affects care planning, risk adjustment accuracy, and total cost of care for MA plans.
How does CMS-HCC V28 affect dementia risk adjustment?
V28 classifies dementia into three severity-based HCC tiers: HCC 125 (severe), HCC 126 (moderate), and HCC 127 (mild or unspecified). All carry a RAF coefficient of 0.341. The shift requires documentation of behavioral disturbance and severity level, not just the dementia type, making clinical specificity more important than under V24.
How can Neurotrack help MA plans close the dementia detection gap?
Neurotrack provides a cognitive care enablement platform with clinically validated digital assessments that detect impairment at the MCI stage. Assessments can be self-administered, completed in minutes, and produce EHR-ready documentation aligned with V28 coding requirements.
What is the GUIDE Model and how does it relate to dementia detection?
The GUIDE Model is a CMS demonstration program running from 2024 through 2032 that provides care coordination, caregiver support, and respite coverage for Medicare beneficiaries with a documented dementia diagnosis. Neurotrack's early detection capabilities help ensure members receive the diagnosis needed to access GUIDE benefits.
Why does health equity matter in dementia screening for MA plans?
Black and Hispanic beneficiaries, dual-eligible members, and rural populations are disproportionately affected by undiagnosed dementia. Neurotrack's culturally agnostic digital assessments help plans address these disparities by removing language-dependent barriers and offering remote screening options that reach underserved populations.
What documentation is required for compliant dementia coding under V28?
Providers must document using MEAT criteria (Monitor, Evaluate, Assess/Address, Treat) during a qualifying face-to-face encounter. For dementia specifically, the note must include severity level, behavioral disturbance status, and any underlying etiology. Problem-list-only entries do not meet RADV audit standards.